A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma.

Alaa Embaby Sanne C F A Huijberts Liqin Wang Rodrigo Leite de Oliveira Hilde Rosing Bastiaan Nuijen Joyce Sanders Ingrid Hofland Charlaine van Steenis Roelof J C Kluin Cor Lieftink Christopher G Smith Christian U Blank Johannes V van Thienen John B A G Haanen Neeltje Steeghs Frans L Opdam Jos H Beijnen Alwin D R Huitema René Bernards Jan H M Schellens Sofie Wilgenhof

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

Intermittent treatment with vorinostat in patients with BRAFi/MEKi-resistant BRAFV600-mutated melanoma is well tolerated. Although the primary endpoint of this study was not met, durable antitumor responses were observed in a minority of patients (9%).

Keyphrases

end stage renal disease
newly diagnosed
histone deacetylase
prognostic factors
tyrosine kinase